Observational studyBMC genomic data2025
Cohort profile: the pharmacogenomics and pharmacokinetics study in Ghanaian HIV patients (GenoPharm-GH).
Observational study in BMC genomic data, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age-Related Variations in Clinical and Biochemical Profiles of People Living With HIV.AIDS research and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe GenoPharm-GH project initiated in 2019, as a longitudinal, multi-site observational cohort study aimed at bridging gaps in understanding the influence of host genetics, pharmacokinetics and comorbidities on treatment outcome among persons living with HIV (PLWH) in Ghana.
methodsThe study is ongoing prospective, longitudinal, multi-site cohort associated with diverse projects being conducted throughout health facilities across Ghana. So far 2044 persons living with HIV (PLWH) aged ≥ 8 years have been registered. These participants are on treatment with antiretroviral therapies (ART). Viral suppression, treatment adherence (self-reported and pill count), clinical data, genetic variations, coinfections, and comorbidities are being studied among these participants. Samples from the studies have been stored in the biorepository in the PGMG laboratory.
resultsAmong the cohort, ≥ 95% are on dolutegravir-based ART; 58% have viral loads less than 50 copies/mL at the latest visit with approximately 10-15% in virologic failure (> 1000cp/mL). Drug metabolite profiling has been undertaken for dolutegravir in mono infections and coinfections with malaria. Pharmacogenetics data for CYP3A4, CYP3A5, UGT1A1 and ApoE have been determined in sub-studies. Coinfections and other non-communicable diseases observed include hepatitis B and C, tuberculosis, pneumonia, diabetes and hypertension indicating the need for integrated care strategies for PLWH. A biorepository has been created for sub-studies and future analysis.
conclusionsThe project provides a strong avenue for translational HIV research, guiding policy and enhancing long-term results. Expanding biobanking and ongoing follow-up should help to improve knowledge of treatment outcomes, support individualised HIV treatment, and direct further therapeutic interventions. Participants are followed up and data updated at regular intervals to understand the dynamics of treatment outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.